# EDGAR Filing Document

**Accession Number:** 0001612940
**File Stem:** 0001104659-23-038375
**Filing Date:** 2023-3
**Character Count:** 2765
**Document Hash:** e07b9633d6f1f310899ccf08649aa10a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-038375.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001104659-23-038375

**CONFORMED SUBMISSION TYPE**: RW

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProQR Therapeutics N.V.
- **CENTRAL INDEX KEY:** 0001612940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** RW

**SEC ACT:**
- **SEC FILE NUMBER:** 333-260780
- **FILM NUMBER:** 23775920

**BUSINESS ADDRESS:**
- **STREET 1:** ZERNIKEDREEF 9
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CK
- **BUSINESS PHONE:** 31 88 166 7000

**MAIL ADDRESS:**
- **STREET 1:** ZERNIKEDREEF 9
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CK

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProQR Therapeutics B.V.
- **DATE OF NAME CHANGE:** 20140708

**ProQR Therapeutics N.V.**

Zernikedreef 9

2333 CK Leiden

The Netherlands

+31 88 166 7000

March 29, 2023

**<u>VIA EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | **ProQR Therapeutics N.V.– Request for Withdrawal of Registration Statement on Form F-3 (File No. 333-260780)** |

---

Ladies and Gentlemen:

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), ProQR Therapeutics N.V. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") consent to the withdrawal of the Company's registration statement on Form F-3 (File No. 333-260780), together with the exhibits and amendments thereto, which was filed on November 4, 2021 (the "Registration Statement"), as of the date hereof or at the earliest practicable date hereafter. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement.

Accordingly, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company's account to be offset against the filing fee for any future registration statement or registration statements.

If you have questions regarding this request, please contact the Company's legal counsel, James Xu, Esq., of Goodwin Procter LLP, at (617) 570-1000.

---

| |
|:---|
| Very truly yours, |
| /s/ Daniel de Boer |
| Chief Executive Officer |

---

cc: René Beukema (Chief Corporate Development Officer & General Counsel) <br> Mitchell S. Bloom (Goodwin Procter LLP)